TCGA-97-A4M0, TCGA-97-A4M0SENT_1,"UUID : GACABZSI-2F21-49E1-SE56-4D7359EF614F","{UUID,:,GACABZSI-2F21-49E1-SE56-4D7359EF614F}","{UUID,:,gacabzsi-2f21-49e1-se56-4d7359ef614f}","{NNP,:,NN}","{0,0,1}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_2,"Tc5A-97-Ame-a1A-PR Redacted","{Tc5A-97-Ame-a1A-PR,Redacted}","{tc5a-97-ame-a1a-pr,redacted}","{NN,JJ}","{2,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_3,"III III III | | | | | | ll | | ll | | l | | | | | | | | | | I | lllllllllllllllllllllllllllllllll","{III,III,III,|,|,|,|,|,|,ll,|,|,ll,|,|,l,|,|,|,|,|,|,|,|,|,|,I,|,lllllllllllllllllllllllllllllllll}","{III,III,III,|,|,|,|,|,|,ll,|,|,ll,|,|,l,|,|,|,|,|,|,|,|,|,|,I,|,lllllllllllllllllllllllllllllllll}","{NNP,NNP,NNP,VBD,CD,CD,NN,CD,CD,NN,NN,CD,NN,CD,NN,NN,CD,CD,NN,CD,CD,NN,CD,NN,CD,NN,PRP,VBP,NN}","{3,3,0,3,6,4,19,9,13,13,13,13,7,15,13,19,16,19,26,21,22,19,24,22,26,3,28,26,28}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_4,"SURGICAL PATHOLOGY REPORT I C A ' o ' 5 ?","{SURGICAL,PATHOLOGY,REPORT,I,C,A,',o,',5,?}","{surgical,pathology,report,I,c,a,',o,',5,?}","{JJ,NN,NN,PRP,NN,NN,'',NN,'',CD,NN}","{3,3,0,3,4,8,0,5,0,11,4}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_5,"av m % / mm nvwwl $ 4-Ir/ypw","{av,m,%,/,mm,nvwwl,$,4-Ir/ypw}","{av,m,%,/,mm,nvwwl,$,4-ir/ypw}","{NN,NN,NN,:,NN,NN,$,JJ}","{0,3,1,1,1,5,6,7}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_6,"COLLECTION DATE : .","{COLLECTION,DATE,:,.}","{COLLECTION,DATE,:,.}","{NNP,NNP,:,.}","{2,0,0,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_7,"P. ; L :7 : .","{P.,;,L,:7,:,.}","{P.,;,l,:7,:,.}","{NNP,:,NN,CD,:,.}","{0,0,1,3,0,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_8,"? 3","{?,3}","{?,3}","{NN,CD}","{0,1}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_9,"5,15 , ; / WV Cgof?mm / 05.14 d 34.1","{5,15,,,;,/,WV,Cgof?mm,/,05.14,d,34.1}","{5,15,,,;,/,wv,cgof?mm,/,05.14,d,34.1}","{CD,,,:,:,NN,NN,:,CD,NN,CD}","{0,0,0,1,1,5,5,5,8,9}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_10,"SPECIMENS : 9 ? 1 .","{SPECIMENS,:,9,?,1,.}","{specimen,:,9,?,1,.}","{NNS,:,CD,NN,CD,.}","{0,0,4,1,4,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_11,"RIGHT UPPER LOBE / ta 2 .","{RIGHT,UPPER,LOBE,/,ta,2,.}","{right,UPPER,LOBE,/,ta,2,.}","{NN,NNP,NNP,:,NN,CD,.}","{3,3,0,5,3,5,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_12,"LEVEL 4 LYMPH NODE , RIGHT , o / .","{LEVEL,4,LYMPH,NODE,,,RIGHT,,,o,/,.}","{level,4,LYMPH,NODE,,,RIGHT,,,o,/,.}","{NN,CD,NNP,NNP,,,NNP,,,NN,:,.}","{4,4,4,0,0,8,0,4,8,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_13,", / , , , 3 .","{,,/,,,,,,,3,.}","{,,/,,,,,,,3,.}","{,,:,,,,,,,CD,.}","{0,0,0,0,0,2,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_14,"LEVEL 10 LYMPH NODE , RIGHT 4 .","{LEVEL,10,LYMPH,NODE,,,RIGHT,4,.}","{level,10,LYMPH,NODE,,,RIGHT,4,.}","{NN,CD,NNP,NNP,,,NNP,CD,.}","{4,4,4,0,0,4,6,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_15,"LEVEL 7 LYMPH NODE , RIGHT 5 .","{LEVEL,7,LYMPH,NODE,,,RIGHT,5,.}","{level,7,LYMPH,NODE,,,RIGHT,5,.}","{NN,CD,NNP,NNP,,,NNP,CD,.}","{4,4,4,0,0,4,6,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_16,"LEVEL 11 LYMPH NODE , RIGHT SEE ADDENDUM","{LEVEL,11,LYMPH,NODE,,,RIGHT,SEE,ADDENDUM}","{level,11,LYMPH,NODE,,,RIGHT,see,addendum}","{NN,CD,NNP,NNP,,,NNP,VBP,NNS}","{4,4,4,7,0,4,0,7}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_17,"Reason For Addendum # 1 : Molecular Studies Reason For Addendum # 2 : Molecular Studies DIAGNOSIS :","{Reason,For,Addendum,#,1,:,Molecular,Studies,Reason,For,Addendum,#,2,:,Molecular,Studies,DIAGNOSIS,:}","{reason,for,Addendum,#,1,:,molecular,study,reason,for,Addendum,#,2,:,molecular,study,diagnosis,:}","{NN,IN,NNP,#,CD,:,JJ,NNS,NN,IN,NNP,#,CD,:,JJ,NNS,NNS,:}","{0,0,1,5,1,0,9,9,1,0,9,13,11,0,16,1,16,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_18,"1 .","{1,.}","{1,.}","{LS,.}","{0,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_19,"LUNG , RIGHT UPPER LOBE : LOBECTOMY - ADENOCARCINOMA , ACINAR PREDOMINANT ( 2.2 CM ) , WITH VISCERAL PLEURAL INVASION CONFIRMED BY AN ELASTIN STAIN ( SEE NOTE ) .","{LUNG,,,RIGHT,UPPER,LOBE,:,LOBECTOMY,-,ADENOCARCINOMA,,,ACINAR,PREDOMINANT,(,2.2,CM,),,,WITH,VISCERAL,PLEURAL,INVASION,CONFIRMED,BY,AN,ELASTIN,STAIN,(,SEE,NOTE,),.}","{lung,,,RIGHT,UPPER,LOBE,:,lobectomy,-,adenocarcinoma,,,ACINAR,predominant,(,2.2,cm,),,,with,visceral,pleural,INVASION,confirm,by,a,ELASTIN,stain,(,see,note,),.}","{NN,,,NNP,NNP,NNP,:,NN,:,NN,,,NNP,JJ,NN,CD,NN,NN,,,IN,JJ,JJ,NNP,VBD,IN,DT,NNP,NN,CD,VBP,VB,CD,.}","{0,0,5,5,1,0,1,0,22,0,13,13,9,16,16,13,0,0,21,21,22,1,0,26,26,28,28,22,28,22,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_20,"- THE BRONCHIAL AND VASCULAR MARGINS ARE FREE OF TUMOR .","{-,THE,BRONCHIAL,AND,VASCULAR,MARGINS,ARE,FREE,OF,TUMOR,.}","{-,the,bronchial,and,vascular,margin,be,free,of,tumor,.}","{:,DT,NN,CC,NN,NNS,VBP,NNS,IN,NN,.}","{0,3,8,0,6,3,8,0,0,8,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_21,"- TWO LYMPH NODES , NEGATIVE FOR CARCINOMA ( 0/2 ) .","{-,TWO,LYMPH,NODES,,,NEGATIVE,FOR,CARCINOMA,(,0/2,),.}","{-,two,lymph,node,,,NEGATIVE,for,CARCINOMA,(,0/2,),.}","{:,CD,NN,NNS,,,NNP,IN,NNP,CD,CD,NN,.}","{0,4,4,0,0,4,0,4,8,11,8,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_22,"Note : The tumor consists of acinar ( 40 % ) , papillary ( 30 % ) , micropapillary ( 20 % ) and Iepidic ( 10 % ) components and measures 2.2 cm in greatest dimension microscopically .","{Note,:,The,tumor,consists,of,acinar,(,40,%,),,,papillary,(,30,%,),,,micropapillary,(,20,%,),and,Iepidic,(,10,%,),components,and,measures,2.2,cm,in,greatest,dimension,microscopically,.}","{note,:,the,tumor,consist,of,acinar,(,40,%,),,,papillary,(,30,%,),,,micropapillary,(,20,%,),and,iepidic,(,10,%,),component,and,measure,2.2,cm,in,greatest,dimension,microscopically,.}","{VB,:,DT,NN,VBZ,IN,JJ,NN,CD,NN,CD,,,JJ,NN,CD,NN,CD,,,JJ,NN,CD,NN,CD,CC,JJ,NN,CD,NN,CD,NNS,CC,NNS,CD,NN,IN,JJS,NN,RB,.}","{0,0,4,5,1,0,8,5,10,17,10,0,14,11,16,17,30,0,20,17,22,20,20,0,26,30,28,26,30,34,0,30,34,8,0,37,34,5,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_23,"Results of mutational studies will be reported in addenda .","{Results,of,mutational,studies,will,be,reported,in,addenda,.}","{result,of,mutational,study,will,be,report,in,addendum,.}","{NNS,IN,JJ,NNS,MD,VB,VBN,IN,NN,.}","{7,0,4,1,7,7,0,0,7,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_24,"2 .","{2,.}","{2,.}","{LS,.}","{0,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_25,"LYMPH NODE , RIGHT LEVEL 4 : BIOPSY - THREE LYMPH N ODES , NEGATIVE FOR CARCINOMA ( 0/3 ) .","{LYMPH,NODE,,,RIGHT,LEVEL,4,:,BIOPSY,-,THREE,LYMPH,N,ODES,,,NEGATIVE,FOR,CARCINOMA,(,0/3,),.}","{lymph,node,,,right,level,4,:,biopsy,-,three,lymph,n,ode,,,NEGATIVE,for,CARCINOMA,(,0/3,),.}","{NN,NN,,,NN,NN,CD,:,NN,:,CD,NN,NN,NNS,,,NNP,IN,NNP,CD,CD,NN,.}","{2,0,0,5,2,5,0,2,0,13,13,13,8,0,13,0,15,17,20,15,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_26,"3 .","{3,.}","{3,.}","{LS,.}","{0,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_27,"LYMPH NODE , RIGHT LEVEL 10 : BIOPSY - ONE LYMPH NODE , NEGATIVE FOR CARCINOMA ( 0/1 ) .","{LYMPH,NODE,,,RIGHT,LEVEL,10,:,BIOPSY,-,ONE,LYMPH,NODE,,,NEGATIVE,FOR,CARCINOMA,(,0/1,),.}","{lymph,node,,,right,level,10,:,biopsy,-,one,lymph,node,,,NEGATIVE,for,CARCINOMA,(,0/1,),.}","{NN,NN,,,NN,NN,CD,:,NN,:,CD,NN,NN,,,NNP,IN,NNP,CD,CD,NN,.}","{2,0,0,5,2,5,0,2,0,12,12,8,0,12,0,14,16,19,14,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_28,"4 .","{4,.}","{4,.}","{LS,.}","{0,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_29,"LYMPH N ODE , RIGHT LEVEL 7 : BIOPSY - ONE LYMPH NODE , NEGATIVE FOR CARCINOMA ( 0/1 ) .","{LYMPH,N,ODE,,,RIGHT,LEVEL,7,:,BIOPSY,-,ONE,LYMPH,NODE,,,NEGATIVE,FOR,CARCINOMA,(,0/1,),.}","{lymph,n,ode,,,right,level,7,:,biopsy,-,one,lymph,node,,,NEGATIVE,for,CARCINOMA,(,0/1,),.}","{NN,NN,NN,,,NN,NN,CD,:,NN,:,CD,NN,NN,,,NNP,IN,NNP,CD,CD,NN,.}","{3,3,0,0,6,3,6,0,3,0,13,13,9,0,13,0,15,17,20,15,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_30,"5 .","{5,.}","{5,.}","{CD,.}","{0,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_31,"LYMPH NODE , RIGHT LEVEL 11 : BIOPSY - ONE LYMPH NODE , NEGATIVE FOR CARCINOMA ( 0/1 ) .","{LYMPH,NODE,,,RIGHT,LEVEL,11,:,BIOPSY,-,ONE,LYMPH,NODE,,,NEGATIVE,FOR,CARCINOMA,(,0/1,),.}","{lymph,node,,,right,level,11,:,biopsy,-,one,lymph,node,,,NEGATIVE,for,CARCINOMA,(,0/1,),.}","{NN,NN,,,NN,NN,CD,:,NN,:,CD,NN,NN,,,NNP,IN,NNP,CD,CD,NN,.}","{2,0,0,5,2,5,0,2,0,12,12,8,0,12,0,14,16,19,14,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_32,"Specimens : 1 : RIGHT UPPER LOBE 2 : LEVEL 4 LYMPH NODE , RIGHT 3 : LEVEL 10 LYMPH NODE , RIGHT 4 : LEVEL 7 LYMPH NODE , RIGHT 5 : LEVEL 11 LYMPH NODE , RIGHT","{Specimens,:,1,:,RIGHT,UPPER,LOBE,2,:,LEVEL,4,LYMPH,NODE,,,RIGHT,3,:,LEVEL,10,LYMPH,NODE,,,RIGHT,4,:,LEVEL,7,LYMPH,NODE,,,RIGHT,5,:,LEVEL,11,LYMPH,NODE,,,RIGHT}","{specimen,:,1,:,RIGHT,UPPER,lobe,2,:,level,4,LYMPH,NODE,,,RIGHT,3,:,level,10,LYMPH,NODE,,,RIGHT,4,:,level,7,LYMPH,NODE,,,RIGHT,5,:,level,11,LYMPH,NODE,,,RIGHT}","{NNS,:,CD,:,NNP,NNP,NN,CD,:,NN,CD,NNP,NNP,,,NNP,CD,:,NN,CD,NNP,NNP,,,NNP,CD,:,NN,CD,NNP,NNP,,,NNP,CD,:,NN,CD,NNP,NNP,,,NNP}","{0,0,1,0,6,3,6,7,0,13,13,13,6,0,13,15,0,21,21,21,6,0,21,23,0,29,29,29,6,0,29,31,0,37,37,37,6,0,37}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_33,"LUNG : Resection SPECIMEN Specimen : Lobe ( s ) of lung ( specify ) right upper Procedure : Lobectomy Specimen Laterality : Right Tumor Site : Upper lobe Tumor Focality : Unifocal TUMOR Histologic Type : Adenocarcinoma , mixed subtype Histologic Grade : G2 : Moderately differentiated EXTENT Tumor Size : Greatest dimension ( cm ) 2.2 cm Visceral Pleura Invasion : Present MARGINS Bronchial Margin Bronchial Margin Involvement by Invasive Carcinoma : Uninvolved by invasive carcinoma Vascular Margin : Uninvolved by invasive carcinoma ACCESSORY FINDINGS Lymph-Vascular Invasion : Not identified STAGE ( pTNM ) Primary Tumor ( pT ) : pT2a : Tumor greater than 3 em , but 5 cm or less in greatest dimension surrounded by lung or visceral pleura without bronchoscopic evidence of invasion more proximal than the lobar bronchus ( i.e. , not in the main bronchus ) ; or Tumor 5 cm or less in greatest dimension with any of the following features of extent : involves main bronchus , 2 cm or more distal to the carina ; invades the visceral pleura ; associated with atelectasis or obstructive pneumonitis that extends to the hilar region but does not inolve the entire lung Regional Lymph Nodes ( pN ) pNo : No regional lymph node metastasis Number Examined","{LUNG,:,Resection,SPECIMEN,Specimen,:,Lobe,(,s,),of,lung,(,specify,),right,upper,Procedure,:,Lobectomy,Specimen,Laterality,:,Right,Tumor,Site,:,Upper,lobe,Tumor,Focality,:,Unifocal,TUMOR,Histologic,Type,:,Adenocarcinoma,,,mixed,subtype,Histologic,Grade,:,G2,:,Moderately,differentiated,EXTENT,Tumor,Size,:,Greatest,dimension,(,cm,),2.2,cm,Visceral,Pleura,Invasion,:,Present,MARGINS,Bronchial,Margin,Bronchial,Margin,Involvement,by,Invasive,Carcinoma,:,Uninvolved,by,invasive,carcinoma,Vascular,Margin,:,Uninvolved,by,invasive,carcinoma,ACCESSORY,FINDINGS,Lymph-Vascular,Invasion,:,Not,identified,STAGE,(,pTNM,),Primary,Tumor,(,pT,),:,pT2a,:,Tumor,greater,than,3,em,,,but,5,cm,or,less,in,greatest,dimension,surrounded,by,lung,or,visceral,pleura,without,bronchoscopic,evidence,of,invasion,more,proximal,than,the,lobar,bronchus,(,i.e.,,,not,in,the,main,bronchus,),;,or,Tumor,5,cm,or,less,in,greatest,dimension,with,any,of,the,following,features,of,extent,:,involves,main,bronchus,,,2,cm,or,more,distal,to,the,carina,;,invades,the,visceral,pleura,;,associated,with,atelectasis,or,obstructive,pneumonitis,that,extends,to,the,hilar,region,but,does,not,inolve,the,entire,lung,Regional,Lymph,Nodes,(,pN,),pNo,:,No,regional,lymph,node,metastasis,Number,Examined}","{lung,:,Resection,SPECIMEN,Specimen,:,lobe,(,s,),of,lung,(,specify,),right,upper,Procedure,:,Lobectomy,Specimen,Laterality,:,Right,tumor,site,:,Upper,lobe,tumor,focality,:,unifocal,tumor,histologic,type,:,adenocarcinoma,,,mixed,subtype,histologic,Grade,:,g2,:,moderately,differentiate,EXTENT,tumor,size,:,greatest,dimension,(,cm,),2.2,cm,visceral,Pleura,Invasion,:,present,margin,bronchial,margin,bronchial,margin,involvement,by,Invasive,Carcinoma,:,uninvolved,by,invasive,carcinoma,vascular,margin,:,uninvolve,by,invasive,carcinoma,accessory,finding,lymph-vascular,Invasion,:,not,identify,stage,(,ptnm,),primary,tumor,(,pt,),:,pt2a,:,tumor,greater,than,3,em,,,but,5,cm,or,less,in,greatest,dimension,surround,by,lung,or,visceral,pleuron,without,bronchoscopic,evidence,of,invasion,more,proximal,than,the,lobar,bronchus,(,i.e.,,,not,in,the,main,bronchus,),;,or,tumor,5,cm,or,less,in,greatest,dimension,with,any,of,the,follow,feature,of,extent,:,involve,main,bronchus,,,2,cm,or,more,distal,to,the,carina,;,invade,the,visceral,pleuron,;,associate,with,atelectasis,or,obstructive,pneumonitis,that,extend,to,the,hilar,region,but,do,not,inolve,the,entire,lung,Regional,Lymph,Nodes,(,pn,),pno,:,no,regional,lymph,node,metastasis,number,examine}","{NN,:,NNP,NNP,NNP,:,NN,CD,NNS,CD,IN,NN,NN,VB,RB,JJ,JJ,NNP,:,NNP,NNP,NNP,:,NNP,NN,NN,:,NNP,NN,NN,NN,:,JJ,NN,JJ,NN,:,NN,,,JJ,NN,JJ,NNP,:,NN,:,RB,VBN,NNP,NN,NN,:,JJS,NN,CD,NN,NN,CD,NN,JJ,NNP,NNP,:,JJ,NNS,JJ,NN,JJ,NN,NN,IN,NNP,NNP,:,JJ,IN,JJ,NN,JJ,NN,:,VBN,IN,JJ,NN,NN,NNS,JJ,NNP,:,RB,VBN,NN,CD,NN,CD,JJ,NN,CD,NN,CD,:,NN,:,NN,JJR,IN,CD,NN,,,CC,CD,NN,CC,JJR,IN,JJS,NN,VBN,IN,NN,CC,JJ,NN,IN,JJ,NN,IN,NN,RBR,JJ,IN,DT,JJ,NN,CD,FW,,,RB,IN,DT,JJ,NN,NN,:,CC,NN,CD,NN,CC,JJR,IN,JJS,NN,IN,DT,IN,DT,VBG,NNS,IN,NN,:,VBZ,JJ,NNS,,,CD,NN,CC,JJR,JJ,TO,DT,NN,:,VBZ,DT,JJ,NN,:,VBN,IN,NN,CC,JJ,NN,WDT,VBZ,TO,DT,JJ,NN,CC,VBZ,RB,VB,DT,JJ,NN,NNP,NNP,NNP,CD,NN,CD,NN,:,DT,JJ,NN,NN,NN,NN,VBN}","{215,0,215,215,215,0,215,215,215,215,215,215,215,215,215,215,215,215,0,215,215,215,0,215,215,215,0,215,215,215,215,0,215,215,215,215,0,215,0,215,215,215,215,0,215,0,215,215,215,215,215,0,215,215,215,215,215,215,215,215,215,215,0,215,215,215,215,215,215,215,215,215,215,0,215,215,215,215,215,215,0,215,215,215,215,215,215,215,215,0,215,215,215,215,215,215,215,215,215,215,215,0,215,0,215,215,215,215,215,0,215,215,215,215,215,215,215,215,215,215,215,215,215,215,215,215,215,215,215,215,215,215,215,215,215,215,215,0,215,215,215,215,215,215,0,215,215,215,215,215,215,215,215,215,215,215,215,215,215,215,215,215,0,215,215,215,0,215,215,215,215,215,215,215,215,0,215,215,215,215,0,215,215,215,215,215,215,215,215,215,215,215,215,215,215,215,215,215,215,215,215,215,215,215,215,215,215,0,215,215,215,215,215,215,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_34,"8 Number Involved o Distant Metastases ( pM ) : Not applicable ADDITIONAL N ON-TUMOR Additional Pathologic Finding ( s ) : Emphysema","{8,Number,Involved,o,Distant,Metastases,(,pM,),:,Not,applicable,ADDITIONAL,N,ON-TUMOR,Additional,Pathologic,Finding,(,s,),:,Emphysema}","{8,Number,involve,o,distant,metastase,(,pm,),:,not,applicable,additional,n,on-tumor,additional,pathologic,find,(,s,),:,Emphysema}","{CD,NNP,VBN,NN,JJ,NNS,VBP,NN,CD,:,RB,JJ,JJ,NN,NN,JJ,JJ,VBG,NN,NNS,CD,:,NNP}","{2,7,2,6,6,3,0,7,8,0,12,15,15,15,8,17,15,17,20,18,20,0,20}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_35,"Pathologist","{Pathologist}","{pathologist}","{NN}","{0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_36,"CLINICAL HISTORY AND PRE ? OPERATIVE DIAGNOSIS :","{CLINICAL,HISTORY,AND,PRE,?,OPERATIVE,DIAGNOSIS,:}","{clinical,history,and,pre,?,OPERATIVE,DIAGNOSIS,:}","{JJ,NN,CC,NN,CD,NNP,NNP,:}","{2,0,0,7,7,7,2,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_37,"F ex-smoker ( 35 pack-years ) with a 1.3 cm RUL adenocarcinoma .","{F,ex-smoker,(,35,pack-years,),with,a,1.3,cm,RUL,adenocarcinoma,.}","{f,ex-smoker,(,35,pack-year,),with,a,1.3,cm,rul,adenocarcinoma,.}","{NN,NN,CD,CD,NNS,VBP,IN,DT,CD,NN,NN,NN,.}","{2,6,5,5,2,0,0,12,12,12,12,6,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_38,"MACROSCOPIC DESCRIPTION : The specimen is received in saline in ?ve parts , each labeled with the patient 's name .","{MACROSCOPIC,DESCRIPTION,:,The,specimen,is,received,in,saline,in,?ve,parts,,,each,labeled,with,the,patient,'s,name,.}","{macroscopic,description,:,the,specimen,be,receive,in,saline,in,?ve,part,,,each,label,with,the,patient,'s,name,.}","{JJ,NN,:,DT,NN,VBZ,VBN,IN,NN,IN,NN,NNS,,,DT,VBN,IN,DT,NN,POS,NN,.}","{2,0,0,5,7,7,2,0,7,0,12,7,0,7,14,0,18,20,0,15,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_39,"1 .","{1,.}","{1,.}","{LS,.}","{0,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_40,"Part one is labeled ? right upper lobe ' .","{Part,one,is,labeled,?,right,upper,lobe,',.}","{Part,one,be,label,?,right,upper,lobe,',.}","{NNP,CD,VBZ,VBN,RB,JJ,JJ,NN,'',.}","{4,1,4,0,4,8,8,4,0,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_41,"It consists ofa right upper lobe of the lung measuring 16 x 10 x 3.5 cm .","{It,consists,ofa,right,upper,lobe,of,the,lung,measuring,16,x,10,x,3.5,cm,.}","{it,consist,ofa,right,upper,lobe,of,the,lung,measure,16,x,10,x,3.5,cm,.}","{PRP,VBZ,RB,JJ,JJ,NN,IN,DT,NN,VBG,CD,CC,CD,CC,CD,NN,.}","{2,0,4,6,6,13,0,9,6,9,10,0,2,0,16,2,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_42,"The bronchial margin measures 1.1 cm and vascular margin measures 1 cm at the hilum .","{The,bronchial,margin,measures,1.1,cm,and,vascular,margin,measures,1,cm,at,the,hilum,.}","{the,bronchial,margin,measure,1.1,cm,and,vascular,margin,measure,1,cm,at,the,hilum,.}","{DT,JJ,NN,NNS,CD,NN,CC,JJ,NN,NNS,CD,NN,IN,DT,NN,.}","{4,4,4,0,6,4,0,10,10,6,12,4,0,15,12,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_43,"The staple line measures 12 cm in length which is shaved and the parenchyma around it is inked blue .","{The,staple,line,measures,12,cm,in,length,which,is,shaved,and,the,parenchyma,around,it,is,inked,blue,.}","{the,staple,line,measure,12,cm,in,length,which,be,shave,and,the,parenchyma,around,it,be,ink,blue,.}","{DT,JJ,NN,NNS,CD,NN,IN,NN,WDT,VBZ,VBN,CC,DT,NN,IN,PRP,VBZ,VBN,JJ,.}","{4,4,4,18,6,4,0,4,11,11,8,0,14,4,0,14,18,0,18,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_44,"The pleura is grey-pink , glistening and received with a pre cut area at the lower aspect of the lung .","{The,pleura,is,grey-pink,,,glistening,and,received,with,a,pre,cut,area,at,the,lower,aspect,of,the,lung,.}","{the,pleuron,be,grey-pink,,,glistening,and,receive,with,a,pre,cut,area,at,the,lower,aspect,of,the,lung,.}","{DT,NN,VBZ,JJ,,,JJ,CC,VBN,IN,DT,JJ,NN,NN,IN,DT,JJR,NN,IN,DT,NN,.}","{2,8,6,6,0,0,0,6,0,13,13,13,8,0,17,17,8,0,20,17,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_45,"At the pre cut area there is a grey-tan ?rm nodular area measuring 1.2 x 1 cm , located 3.2 cm from the hilum and 3.8 cm from the stapled line margin .","{At,the,pre,cut,area,there,is,a,grey-tan,?rm,nodular,area,measuring,1.2,x,1,cm,,,located,3.2,cm,from,the,hilum,and,3.8,cm,from,the,stapled,line,margin,.}","{at,the,pre,cut,area,there,be,a,grey-tan,?rm,nodular,area,measure,1.2,x,1,cm,,,located,3.2,cm,from,the,hilum,and,3.8,cm,from,the,stapled,line,margin,.}","{IN,DT,JJ,NN,NN,EX,VBZ,DT,NN,NN,JJ,NN,VBG,CD,CC,CD,NN,,,JJ,CD,NN,IN,DT,NN,CC,CD,NN,IN,DT,JJ,NN,NN,.}","{0,5,5,5,7,7,0,12,12,12,12,7,12,13,0,17,14,0,21,19,14,0,24,21,0,27,13,0,32,32,32,27,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_46,"The remainder of the parenchyma is pink-red , blotchy and crepitant .","{The,remainder,of,the,parenchyma,is,pink-red,,,blotchy,and,crepitant,.}","{the,remainder,of,the,parenchyma,be,pink-red,,,blotchy,and,crepitant,.}","{DT,NN,IN,DT,NN,VBZ,JJ,,,JJ,CC,JJ,.}","{2,11,0,5,2,7,0,0,7,0,7,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_47,"No other nodule grossly identi?ed .","{No,other,nodule,grossly,identi?ed,.}","{no,other,nodule,grossly,identi?ed,.}","{DT,JJ,NN,RB,JJ,.}","{3,3,5,5,0,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_48,"Representative sections are submitted .","{Representative,sections,are,submitted,.}","{Representative,section,be,submit,.}","{NNP,NNS,VBP,VBN,.}","{2,4,4,0,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_49,"2 .","{2,.}","{2,.}","{LS,.}","{0,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_50,"Part two is labeled ' level 4 lymph node right ? .","{Part,two,is,labeled,',level,4,lymph,node,right,?,.}","{Part,two,be,label,',level,4,lymph,node,right,?,.}","{NNP,CD,VBZ,VBN,'',NN,CD,NN,NN,JJ,NN,.}","{4,1,4,0,0,9,9,9,11,11,4,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_51,"It consists of three anthracotic lymph nodes measuring from 0.3 em up to 1.3 cm in largest dimension .","{It,consists,of,three,anthracotic,lymph,nodes,measuring,from,0.3,em,up,to,1.3,cm,in,largest,dimension,.}","{it,consist,of,three,anthracotic,lymph,node,measure,from,0.3,em,up,to,1.3,cm,in,largest,dimension,.}","{PRP,VBZ,IN,CD,JJ,NN,NNS,VBG,IN,CD,NN,IN,TO,CD,NN,IN,JJS,NN,.}","{2,0,0,7,7,7,2,7,0,11,8,14,14,15,2,0,18,15,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_52,"Entirely submitted in one cassette .","{Entirely,submitted,in,one,cassette,.}","{entirely,submit,in,one,cassette,.}","{RB,VBN,IN,CD,NN,.}","{2,0,0,5,2,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_53,"3 .","{3,.}","{3,.}","{LS,.}","{0,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_54,"Part three is labeled ' level 10 lymph node right ' .","{Part,three,is,labeled,',level,10,lymph,node,right,',.}","{Part,three,be,label,',level,10,lymph,node,right,',.}","{NNP,CD,VBZ,VBN,'',NN,CD,NN,NN,NN,'',.}","{4,1,4,0,0,4,6,4,10,8,0,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_55,"It consists of one anthracotic lymph node measuring 1 x 1 x 0.5 cm .","{It,consists,of,one,anthracotic,lymph,node,measuring,1,x,1,x,0.5,cm,.}","{it,consist,of,one,anthracotic,lymph,node,measure,1,x,1,x,0.5,cm,.}","{PRP,VBZ,IN,CD,JJ,NN,NN,VBG,CD,CC,CD,CC,CD,NN,.}","{2,0,0,7,7,7,8,2,11,0,8,0,14,11,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_56,"Entirely submitted in one cassette .","{Entirely,submitted,in,one,cassette,.}","{entirely,submit,in,one,cassette,.}","{RB,VBN,IN,CD,NN,.}","{2,0,0,5,2,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_57,"4 .","{4,.}","{4,.}","{LS,.}","{0,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_58,"Part four is labeled ? level 7 lymph node right ' .","{Part,four,is,labeled,?,level,7,lymph,node,right,',.}","{Part,four,be,label,?,level,7,lymph,node,right,',.}","{NNP,CD,VBZ,VBN,JJ,NN,CD,NN,NN,NN,'',.}","{4,1,4,0,10,10,10,10,10,4,0,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_59,"It consists of one anthracotic lymph node measuring 0.6 x 0.6 x 0.3 cm .","{It,consists,of,one,anthracotic,lymph,node,measuring,0.6,x,0.6,x,0.3,cm,.}","{it,consist,of,one,anthracotic,lymph,node,measure,0.6,x,0.6,x,0.3,cm,.}","{PRP,VBZ,IN,CD,JJ,NN,NN,VBG,CD,CC,CD,CC,CD,NN,.}","{2,0,0,7,7,7,8,2,11,0,8,0,14,11,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_60,"Entirely submitted in one cassette .","{Entirely,submitted,in,one,cassette,.}","{entirely,submit,in,one,cassette,.}","{RB,VBN,IN,CD,NN,.}","{2,0,0,5,2,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_61,"5 .","{5,.}","{5,.}","{CD,.}","{0,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_62,"Part ?ve is labeled ' level 11 lymph node right ' .","{Part,?ve,is,labeled,',level,11,lymph,node,right,',.}","{Part,?ve,be,label,',level,11,lymph,node,right,',.}","{NNP,NN,VBZ,VBN,'',NN,CD,NN,NN,NN,'',.}","{2,4,4,0,0,4,6,4,10,8,0,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_63,"It consists of one anthracotic lymph node measuring 1 x 0.8 x 0.5 cm .","{It,consists,of,one,anthracotic,lymph,node,measuring,1,x,0.8,x,0.5,cm,.}","{it,consist,of,one,anthracotic,lymph,node,measure,1,x,0.8,x,0.5,cm,.}","{PRP,VBZ,IN,CD,JJ,NN,NN,VBG,CD,CC,CD,CC,CD,NN,.}","{2,0,0,7,7,7,8,2,11,0,8,0,14,11,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_64,"Entirely submitted in one cassette .","{Entirely,submitted,in,one,cassette,.}","{entirely,submit,in,one,cassette,.}","{RB,VBN,IN,CD,NN,.}","{2,0,0,5,2,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_65,"SUMMARY OF SECTIONS : lA bronchial margin , shaved 1B vascular margin , shaved lC-lF nodular area 1G stapled line margin 1H two lymph nodes from the hilum 2A entirely submitted 3A entirely submitted 4A entirely submitted SA entirely submitted","{SUMMARY,OF,SECTIONS,:,lA,bronchial,margin,,,shaved,1B,vascular,margin,,,shaved,lC-lF,nodular,area,1G,stapled,line,margin,1H,two,lymph,nodes,from,the,hilum,2A,entirely,submitted,3A,entirely,submitted,4A,entirely,submitted,SA,entirely,submitted}","{summary,of,section,:,la,bronchial,margin,,,shave,1b,vascular,margin,,,shave,lc-lf,nodular,area,1g,staple,line,margin,1h,two,lymph,node,from,the,hilum,2a,entirely,submit,3a,entirely,submit,4a,entirely,submit,SA,entirely,submit}","{NN,IN,NNS,:,NN,JJ,NN,,,VBD,NN,JJ,NN,,,VBD,NN,JJ,NN,NN,VBD,NN,NN,NN,CD,NN,NNS,IN,DT,NN,NN,RB,VBD,NN,RB,VBD,NN,RB,VBD,NNP,RB,VBD}","{9,0,1,0,7,7,1,0,0,12,12,9,0,12,14,18,18,19,15,22,22,19,25,25,31,0,29,29,25,31,22,34,34,31,37,37,34,40,40,37}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_66,"SPECIAL PROCEDURES :","{SPECIAL,PROCEDURES,:}","{special,procedure,:}","{JJ,NNS,:}","{2,0,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_67,"Final Diagnosis performed by","{Final,Diagnosis,performed,by}","{final,diagnosis,perform,by}","{JJ,NN,VBN,IN}","{2,3,0,3}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_68,"ADDENDUM # 1 :","{ADDENDUM,#,1,:}","{ADDENDUM,#,1,:}","{NNP,#,CD,:}","{0,3,1,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_69,"INTEGRATED ONCOLOGY","{INTEGRATED,ONCOLOGY}","{integrate,oncology}","{VBN,NN}","{0,1}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_70,"MOLECULAR ONCOLOGY KRAS MUTATION ANALYSIS","{MOLECULAR,ONCOLOGY,KRAS,MUTATION,ANALYSIS}","{molecular,ONCOLOGY,KRAS,MUTATION,ANALYSIS}","{JJ,NNP,NNP,NNP,NNP}","{5,5,5,5,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_71,"Referring Physician : Body Site : Lung Specimen Type : Slides Clinical Data : Adenocarcinoma","{Referring,Physician,:,Body,Site,:,Lung,Specimen,Type,:,Slides,Clinical,Data,:,Adenocarcinoma}","{refer,physician,:,body,site,:,lung,specimen,type,:,slide,clinical,datum,:,adenocarcinoma}","{VBG,NN,:,NN,NN,:,NN,NN,NN,:,NNS,JJ,NNS,:,NN}","{0,1,0,5,2,0,9,9,2,0,2,13,11,0,11}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_72,"RESULTS : Positive for a p. Gl2C ( c. 34G > T ) mutation in codon 12 of the KRAS gene .","{RESULTS,:,Positive,for,a,p.,Gl2C,(,c.,34G,>,T,),mutation,in,codon,12,of,the,KRAS,gene,.}","{result,:,positive,for,a,p.,gl2c,(,c.,34g,>,t,),mutation,in,codon,12,of,the,KRAS,gene,.}","{NNS,:,JJ,IN,DT,NN,NN,CD,NN,NN,JJR,NN,NN,NN,IN,NN,CD,IN,DT,NNP,NN,.}","{0,0,1,0,10,10,10,10,10,3,14,14,14,10,0,14,16,0,21,21,16,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_73,"INTERPRETATION : Mutations in the KRAS gene are reported to correlate with poor prognosis and resistance to tyrosine kinase inhibitor therapies in patients with non-small-cell lung cancer .","{INTERPRETATION,:,Mutations,in,the,KRAS,gene,are,reported,to,correlate,with,poor,prognosis,and,resistance,to,tyrosine,kinase,inhibitor,therapies,in,patients,with,non-small-cell,lung,cancer,.}","{interpretation,:,mutation,in,the,KRAS,gene,be,report,to,correlate,with,poor,prognosis,and,resistance,to,tyrosine,kinase,inhibitor,therapy,in,patient,with,non-small-cell,lung,cancer,.}","{NN,:,NNS,IN,DT,NNP,NN,VBP,VBN,TO,VB,IN,JJ,NN,CC,NN,TO,NN,NN,NN,NNS,IN,NNS,IN,JJ,NN,NN,.}","{0,0,9,0,7,7,3,9,1,11,9,0,14,11,0,14,0,21,21,21,11,0,11,0,27,27,23,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_74,"COMMENT : KRAS mutations occur in 15-30 % of non-small-cell lung cancer ( NSCLC )","{COMMENT,:,KRAS,mutations,occur,in,15-30,%,of,non-small-cell,lung,cancer,(,NSCLC,)}","{COMMENT,:,KRAS,mutation,occur,in,15-30,%,of,non-small-cell,lung,cancer,(,nsclc,)}","{NNP,:,NNP,NNS,VBP,IN,CD,NN,IN,JJ,NN,NN,CD,NN,NN}","{5,0,4,1,0,0,8,5,0,12,12,8,15,15,5}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_75,"patients and are strongly associated with adenocarcinoma and smoking history .","{patients,and,are,strongly,associated,with,adenocarcinoma,and,smoking,history,.}","{patient,and,be,strongly,associate,with,adenocarcinoma,and,smoking,history,.}","{NNS,CC,VBP,RB,VBN,IN,NN,CC,NN,NN,.}","{5,5,5,5,0,0,10,0,10,5,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_76,"This assay analyzes codons 12 and 13 in exon 2 of the KRAS gene ; based on the current literature , approximately 98 % of mutations are expected to occur in these codons .","{This,assay,analyzes,codons,12,and,13,in,exon,2,of,the,KRAS,gene,;,based,on,the,current,literature,,,approximately,98,%,of,mutations,are,expected,to,occur,in,these,codons,.}","{this,assay,analyze,codon,12,and,13,in,exon,2,of,the,KRAS,gene,;,base,on,the,current,literature,,,approximately,98,%,of,mutation,be,expect,to,occur,in,these,codon,.}","{DT,NN,VBZ,NNS,CD,CC,CD,IN,NN,CD,IN,DT,NNP,NN,:,VBN,IN,DT,JJ,NN,,,RB,CD,NN,IN,NNS,VBP,VBN,TO,VB,IN,DT,NNS,.}","{2,3,0,3,4,0,3,0,4,9,0,14,14,9,0,0,28,20,20,28,0,23,24,28,0,24,28,3,30,28,0,33,30,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_77,"The analytical sensitivity of the assay is approximately 10 % ; thus mutations present in a low percentage of cells may not be detected .","{The,analytical,sensitivity,of,the,assay,is,approximately,10,%,;,thus,mutations,present,in,a,low,percentage,of,cells,may,not,be,detected,.}","{the,analytical,sensitivity,of,the,assay,be,approximately,10,%,;,thus,mutation,present,in,a,low,percentage,of,cell,may,not,be,detect,.}","{DT,JJ,NN,IN,DT,NN,VBZ,RB,CD,NN,:,RB,NNS,JJ,IN,DT,JJ,NN,IN,NNS,MD,RB,VB,VBN,.}","{3,3,10,0,6,3,10,9,10,0,0,24,24,13,0,18,18,14,0,18,24,24,24,10,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_78,"This test is validated for use in identifying KRAS codon 12 and codon 13 mutations in fresh , frozen , or formalin-?xed paraffin embedded tissue .","{This,test,is,validated,for,use,in,identifying,KRAS,codon,12,and,codon,13,mutations,in,fresh,,,frozen,,,or,formalin-?xed,paraffin,embedded,tissue,.}","{this,test,be,validate,for,use,in,identify,KRAS,codon,12,and,codon,13,mutation,in,fresh,,,frozen,,,or,formalin-?xed,paraffin,embedded,tissue,.}","{DT,NN,VBZ,VBN,IN,NN,IN,VBG,NNP,NN,CD,CC,NN,CD,NNS,IN,JJ,,,JJ,,,CC,JJ,NN,JJ,NN,.}","{2,4,4,0,0,4,0,4,10,8,10,0,10,15,13,0,19,0,8,0,0,23,8,25,23,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_79,"In particular the test performance has been established in samples of colorectal cancer and non-small cell lung carcinoma which harbor these mutations , although several other tissues are also known to harbor KRAS mutations ( e. g. tumors of pancreas , bile duct , ovary , appendix , etc. ) .","{In,particular,the,test,performance,has,been,established,in,samples,of,colorectal,cancer,and,non-small,cell,lung,carcinoma,which,harbor,these,mutations,,,although,several,other,tissues,are,also,known,to,harbor,KRAS,mutations,(,e.,g.,tumors,of,pancreas,,,bile,duct,,,ovary,,,appendix,,,etc.,),.}","{in,particular,the,test,performance,have,be,establish,in,sample,of,colorectal,cancer,and,non-small,cell,lung,carcinoma,which,harbor,these,mutation,,,although,several,other,tissue,be,also,know,to,harbor,KRAS,mutation,(,e.,g.,tumor,of,pancreas,,,bile,duct,,,ovary,,,appendix,,,etc.,),.}","{IN,JJ,DT,NN,NN,VBZ,VBN,VBN,IN,NNS,IN,JJ,NN,CC,JJ,NN,NN,NN,WDT,VBP,DT,NNS,,,IN,JJ,JJ,NNS,VBP,RB,VBN,TO,VB,NNP,NNS,CD,NN,NN,NNS,IN,NN,,,NN,NN,,,NN,,,NN,,,FW,FW,.}","{0,8,5,5,8,8,8,0,0,8,0,13,10,0,18,18,18,10,20,18,22,20,0,30,27,27,30,30,30,8,32,30,34,38,38,38,38,32,0,38,0,43,40,0,40,0,40,0,50,40,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_80,"METHOD/LIMITATIONS : Tissue sections are reviewed by a pathologist and relevant tumor is selected for analysis .","{METHOD/LIMITATIONS,:,Tissue,sections,are,reviewed,by,a,pathologist,and,relevant,tumor,is,selected,for,analysis,.}","{METHOD/LIMITATIONS,:,tissue,section,be,review,by,a,pathologist,and,relevant,tumor,be,select,for,analysis,.}","{NNP,:,NN,NNS,VBP,VBN,IN,DT,NN,CC,JJ,NN,VBZ,VBN,IN,NN,.}","{0,0,4,6,6,1,0,9,6,0,12,14,14,6,0,14,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_81,"DNA is isolated from the sample , quantified and ampli?ed by polymerase chain reaction ( PCR ) using primers to exon 2 of the KRAS gene .","{DNA,is,isolated,from,the,sample,,,quantified,and,ampli?ed,by,polymerase,chain,reaction,(,PCR,),using,primers,to,exon,2,of,the,KRAS,gene,.}","{dna,be,isolate,from,the,sample,,,quantify,and,ampli?ed,by,polymerase,chain,reaction,(,pcr,),use,primer,to,exon,2,of,the,KRAS,gene,.}","{NN,VBZ,VBN,IN,DT,NN,,,VBN,CC,VBN,IN,NN,NN,NN,CD,NN,NN,VBG,NNS,TO,NN,CD,IN,DT,NNP,NN,.}","{10,3,0,0,6,3,0,3,0,3,0,17,17,17,17,17,10,17,18,0,18,21,0,26,26,21,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_82,"PCR products are subjected to single nucleotide primer extension to detect mutations at codons 12 and 13 ; primer extension products are analyzed using capillary gel electrophoresis and ?uorescence detection .","{PCR,products,are,subjected,to,single,nucleotide,primer,extension,to,detect,mutations,at,codons,12,and,13,;,primer,extension,products,are,analyzed,using,capillary,gel,electrophoresis,and,?uorescence,detection,.}","{pcr,product,be,subject,to,single,nucleotide,primer,extension,to,detect,mutation,at,codon,12,and,13,;,primer,extension,product,be,analyze,use,capillary,gel,electrophoresis,and,?uorescence,detection,.}","{NN,NNS,VBP,VBN,TO,JJ,NN,NN,NN,TO,VB,NNS,IN,NNS,CD,CC,CD,:,NN,NN,NNS,VBP,VBN,VBG,JJ,NN,NN,CC,NN,NN,.}","{2,4,4,0,0,9,9,9,4,11,4,11,0,11,14,0,11,0,21,21,23,23,4,23,27,27,24,0,30,27,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_83,"False positive or negative results may occur for reasons that include genetic variants or somatic heterogeneity of the tissue sample .","{False,positive,or,negative,results,may,occur,for,reasons,that,include,genetic,variants,or,somatic,heterogeneity,of,the,tissue,sample,.}","{false,positive,or,negative,result,may,occur,for,reason,that,include,genetic,variant,or,somatic,heterogeneity,of,the,tissue,sample,.}","{JJ,JJ,CC,JJ,NNS,MD,VB,IN,NNS,WDT,VBP,JJ,NNS,CC,JJ,NN,IN,DT,NN,NN,.}","{5,5,0,2,7,7,0,0,7,11,9,13,11,0,16,13,0,20,20,16,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_84,"REFERENCES : NSCLC Mascaux C , Iannino N , et al. .","{REFERENCES,:,NSCLC,Mascaux,C,,,Iannino,N,,,et,al.,.}","{reference,:,nsclc,mascaux,c,,,iannino,n,,,et,al.,.}","{NNS,:,NN,NN,NN,,,NN,NN,,,FW,FW,.}","{0,0,5,5,1,0,8,1,0,11,1,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_85,"British Journal of Cancer , 2005 ; 92:11 -139 Pao W , Wang TY , et al. .","{British,Journal,of,Cancer,,,2005,;,92:11,-139,Pao,W,,,Wang,TY,,,et,al.,.}","{british,Journal,of,Cancer,,,2005,;,92:11,-139,Pao,W,,,Wang,TY,,,et,al.,.}","{JJ,NNP,IN,NNP,,,CD,:,CD,CD,NNP,NNP,,,NNP,NNP,,,FW,FW,.}","{2,0,0,2,0,4,0,11,11,11,2,0,14,11,0,17,11,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_86,"PLoS Medicine , 205 ; 2 ( l ) :57 -61 Eberhard DA , Johnson BE , et al. .","{PLoS,Medicine,,,205,;,2,(,l,),:57,-61,Eberhard,DA,,,Johnson,BE,,,et,al.,.}","{PLoS,Medicine,,,205,;,2,(,l,),:57,-61,Eberhard,DA,,,Johnson,be,,,et,al.,.}","{NNP,NNP,,,CD,:,CD,CD,NN,CD,CD,CD,NNP,NNP,,,NNP,VBP,,,FW,FW,.}","{2,0,0,2,0,8,8,2,13,13,13,13,8,0,16,2,0,19,2,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_87,"J Clin Oncol , 2005 ; 2325900-5909 Han SW , Kim TY , et al. .","{J,Clin,Oncol,,,2005,;,2325900-5909,Han,SW,,,Kim,TY,,,et,al.,.}","{J,Clin,Oncol,,,2005,;,2325900-5909,Han,SW,,,Kim,TY,,,et,al.,.}","{NNP,NNP,NNP,,,CD,:,CD,NNP,NNP,,,NNP,NNP,,,FW,FW,.}","{3,3,0,0,3,0,9,9,3,0,12,9,0,15,9,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_88,"Clin Cancer Res .","{Clin,Cancer,Res,.}","{Clin,Cancer,Res,.}","{NNP,NNP,NNP,.}","{3,3,0,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_89,"2006 ; 12 ( 8 ) :253888888 -2544 CRC DiFiore C , Blanchard F , et al. .","{2006,;,12,(,8,),:253888888,-2544,CRC,DiFiore,C,,,Blanchard,F,,,et,al.,.}","{2006,;,12,(,8,),:253888888,-2544,crc,difiore,c,,,Blanchard,f,,,et,al.,.}","{CD,:,CD,CD,CD,NN,CD,CD,NN,NN,NN,,,NNP,NN,,,FW,FW,.}","{3,0,0,5,3,5,6,11,11,11,3,0,14,11,0,17,3,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_90,"Br J Cancer , 20007 ; 96:1 166-1169 Lievre A , Bachet J - B , et al. .","{Br,J,Cancer,,,20007,;,96:1,166-1169,Lievre,A,,,Bachet,J,-,B,,,et,al.,.}","{br,j,cancer,,,20007,;,96:1,166-1169,Lievre,A,,,Bachet,J,-,b,,,et,al.,.}","{NN,NN,NN,,,CD,:,CD,CD,NNP,NNP,,,NNP,NNP,:,NN,,,FW,FW,.}","{3,3,0,0,3,0,10,10,10,3,0,13,10,0,3,0,18,15,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_91,"Cancer Res , 2006 ; 66:3992 -3995 ,","{Cancer,Res,,,2006,;,66:3992,-3995,,}","{cancer,Res,,,2006,;,66:3992,-3995,,}","{NN,NNP,,,CD,:,CD,CD,,}","{0,1,0,2,0,7,4,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_92,"The test was developed and its performance characteristics determined by The laboratory is regulated under the Clinical Laboratory Improvement Amendments of 1988 ( CLIA ) as quali?ed to perform high complexity clinical testing .","{The,test,was,developed,and,its,performance,characteristics,determined,by,The,laboratory,is,regulated,under,the,Clinical,Laboratory,Improvement,Amendments,of,1988,(,CLIA,),as,quali?ed,to,perform,high,complexity,clinical,testing,.}","{the,test,be,develop,and,its,performance,characteristic,determine,by,the,laboratory,be,regulate,under,the,clinical,laboratory,improvement,amendment,of,1988,(,clium,),as,quali?ed,to,perform,high,complexity,clinical,testing,.}","{DT,NN,VBD,VBN,CC,PRP$,NN,NNS,VBN,IN,DT,NN,VBZ,VBN,IN,DT,JJ,NN,NN,NNS,IN,CD,CD,NN,RB,IN,JJ,TO,VB,JJ,NN,JJ,NN,.}","{2,4,4,0,0,8,8,14,8,0,12,9,14,4,0,20,20,20,20,14,0,24,24,20,27,27,24,29,14,33,33,33,29,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_93,"This particular test is not considered a stand alone test and should be used only in the context of other diagnostic tests or clinical work-up related to treatment decisions .","{This,particular,test,is,not,considered,a,stand,alone,test,and,should,be,used,only,in,the,context,of,other,diagnostic,tests,or,clinical,work-up,related,to,treatment,decisions,.}","{this,particular,test,be,not,consider,a,stand,alone,test,and,should,be,use,only,in,the,context,of,other,diagnostic,test,or,clinical,work-up,related,to,treatment,decision,.}","{DT,JJ,NN,VBZ,RB,VBN,DT,NN,RB,NN,CC,MD,VB,VBN,RB,IN,DT,NN,IN,JJ,JJ,NNS,CC,JJ,NN,JJ,TO,NN,NNS,.}","{3,3,14,6,6,0,10,10,10,6,0,14,14,6,14,0,18,14,0,22,22,18,0,25,14,25,0,29,26,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_94,"Electronically signed by : Date :","{Electronically,signed,by,:,Date,:}","{electronically,sign,by,:,date,:}","{RB,VBN,IN,:,NN,:}","{2,0,2,0,3,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_95,"Addendum # 1 performed by","{Addendum,#,1,performed,by}","{Addendum,#,1,perform,by}","{NNP,#,CD,VBN,IN}","{0,3,1,1,4}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_96,"ADDENDUM # 2 :","{ADDENDUM,#,2,:}","{ADDENDUM,#,2,:}","{NNP,#,CD,:}","{0,3,1,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_97,"INTEGRATED ONCOLOGY","{INTEGRATED,ONCOLOGY}","{integrate,oncology}","{VBN,NN}","{0,1}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_98,"EGFR Mutation Analysis","{EGFR,Mutation,Analysis}","{egfr,mutation,analysis}","{NN,NN,NN}","{0,3,1}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_99,"Referring Physician : .","{Referring,Physician,:,.}","{refer,physician,:,.}","{VBG,NN,:,.}","{0,1,0,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_100,"Body Site : Lung Clinical Data : Adenocarcinoma RESULTS : No mutation detected .","{Body,Site,:,Lung,Clinical,Data,:,Adenocarcinoma,RESULTS,:,No,mutation,detected,.}","{body,site,:,lung,clinical,datum,:,adenocarcinoma,result,:,no,mutation,detect,.}","{NN,NN,:,NN,JJ,NNS,:,NN,NNS,:,DT,NN,VBN,.}","{2,0,0,2,6,4,0,9,2,0,12,13,2,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_101,"INTERPRETATION : No mutations were identi?ed in the sample provided for analysis .","{INTERPRETATION,:,No,mutations,were,identi?ed,in,the,sample,provided,for,analysis,.}","{interpretation,:,no,mutation,be,identi?ed,in,the,sample,provide,for,analysis,.}","{NN,:,DT,NNS,VBD,VBN,IN,DT,NN,VBN,IN,NN,.}","{0,0,4,6,6,1,0,9,6,9,0,10,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_102,"Fewer than 5 % of non-small cell lung carcinoma patients without identi?able mutations are reported to be responsive to EGFR tyrosine kinase inhibitor therapies .","{Fewer,than,5,%,of,non-small,cell,lung,carcinoma,patients,without,identi?able,mutations,are,reported,to,be,responsive,to,EGFR,tyrosine,kinase,inhibitor,therapies,.}","{fewer,than,5,%,of,non-small,cell,lung,carcinoma,patient,without,identi?able,mutation,be,report,to,be,responsive,to,egfr,tyrosine,kinase,inhibitor,therapy,.}","{JJR,IN,CD,NN,IN,JJ,NN,NN,NN,NNS,IN,JJ,NNS,VBP,VBN,TO,VB,JJ,TO,NN,NN,NN,NN,NNS,.}","{15,0,4,1,0,10,10,10,10,4,0,13,10,15,0,18,18,15,0,24,24,24,24,18,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_103,"COMMENT : Forty percent ( 40 % ) or more tumor cellularity is optimal for this mutation analysis .","{COMMENT,:,Forty,percent,(,40,%,),or,more,tumor,cellularity,is,optimal,for,this,mutation,analysis,.}","{COMMENT,:,forty,percent,(,40,%,),or,more,tumor,cellularity,be,optimal,for,this,mutation,analysis,.}","{NNP,:,CD,NN,CD,CD,NN,CD,CC,JJR,NN,NN,VBZ,JJ,IN,DT,NN,NN,.}","{0,0,4,14,7,7,4,4,0,4,12,8,14,1,0,18,18,14,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_104,"The sample submitted showed 80 % tumor cellularity upon pathologist review .","{The,sample,submitted,showed,80,%,tumor,cellularity,upon,pathologist,review,.}","{the,sample,submit,show,80,%,tumor,cellularity,upon,pathologist,review,.}","{DT,NN,VBN,VBD,CD,NN,NN,NN,IN,NN,NN,.}","{2,4,2,0,6,8,8,4,0,11,4,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_105,"A frequently occurring sequence change 2361G > A ( Q787Q ) was identi?ed .","{A,frequently,occurring,sequence,change,2361G,>,A,(,Q787Q,),was,identi?ed,.}","{a,frequently,occur,sequence,change,2361g,>,a,(,q787q,),be,identi?ed,.}","{DT,RB,VBG,NN,NN,NN,JJR,DT,CD,NN,NN,VBD,VBN,.}","{6,3,6,6,6,0,6,11,11,11,13,13,7,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_106,"This polymorphism is known not to have clinical signi?cance .","{This,polymorphism,is,known,not,to,have,clinical,signi?cance,.}","{this,polymorphism,be,know,not,to,have,clinical,signi?cance,.}","{DT,NN,VBZ,VBN,RB,TO,VB,JJ,NN,.}","{2,4,4,0,7,7,4,9,7,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_107,"Mutations in the tyrosine domain of the epidermal growth factor receptor ( EGF R ) gene are reported to be associated with differential responsiveness or resistance to EGFR tyrosine kinase inhibitor ( TKI ) therapies .","{Mutations,in,the,tyrosine,domain,of,the,epidermal,growth,factor,receptor,(,EGF,R,),gene,are,reported,to,be,associated,with,differential,responsiveness,or,resistance,to,EGFR,tyrosine,kinase,inhibitor,(,TKI,),therapies,.}","{mutation,in,the,tyrosine,domain,of,the,epidermal,growth,factor,receptor,(,egf,r,),gene,be,report,to,be,associate,with,differential,responsiveness,or,resistance,to,egfr,tyrosine,kinase,inhibitor,(,tkus,),therapy,.}","{NNS,IN,DT,NN,NN,IN,DT,JJ,NN,NN,NN,CD,NN,NN,NN,NN,VBP,VBN,TO,VB,VBN,IN,JJ,NN,CC,NN,TO,NN,NN,NN,NN,NN,NN,CD,NNS,.}","{18,0,5,5,1,0,16,14,14,14,14,14,14,16,16,5,18,0,21,21,18,0,24,21,0,21,0,33,33,33,33,33,21,35,33,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_108,"The objective response rate among patients with a sensitizing mutation ranges from 55 to 82 % .","{The,objective,response,rate,among,patients,with,a,sensitizing,mutation,ranges,from,55,to,82,%,.}","{the,objective,response,rate,among,patient,with,a,sensitize,mutation,range,from,55,to,82,%,.}","{DT,JJ,NN,NN,IN,NNS,IN,DT,VBG,NN,NNS,IN,CD,TO,CD,NN,.}","{4,4,4,0,0,4,0,11,11,11,6,0,15,15,16,11,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_109,"This assay analyzes exons 18-21 of the EGFR tyrosine kinase domain ; based on the current literature , most mutations in non-small-cell lung carcinoma ( N SCLC ) are expected to occur in these exons .","{This,assay,analyzes,exons,18-21,of,the,EGFR,tyrosine,kinase,domain,;,based,on,the,current,literature,,,most,mutations,in,non-small-cell,lung,carcinoma,(,N,SCLC,),are,expected,to,occur,in,these,exons,.}","{this,assay,analyze,exon,18-21,of,the,egfr,tyrosine,kinase,domain,;,base,on,the,current,literature,,,most,mutation,in,non-small-cell,lung,carcinoma,(,n,sclc,),be,expect,to,occur,in,these,exon,.}","{DT,NN,VBZ,NNS,CD,IN,DT,NN,NN,NN,NN,:,VBN,IN,DT,JJ,NN,,,JJS,NNS,IN,JJ,NN,NN,CD,NN,NN,NN,VBP,VBN,TO,VB,IN,DT,NNS,.}","{2,3,0,3,4,0,11,11,11,11,4,0,0,30,17,17,30,0,20,17,0,24,24,20,28,28,28,30,30,3,32,30,0,35,32,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_110,"Mutations present in less than 10-20 % of extracted DNA may not be detected by this method .","{Mutations,present,in,less,than,10-20,%,of,extracted,DNA,may,not,be,detected,by,this,method,.}","{mutation,present,in,less,than,10-20,%,of,extract,dna,may,not,be,detect,by,this,method,.}","{NNS,JJ,IN,JJR,IN,CD,NN,IN,VBN,NN,MD,RB,VB,VBN,IN,DT,NN,.}","{14,1,0,5,6,7,2,0,10,7,14,14,14,0,0,17,14,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_111,"Mutation status in a sample may change during tumor progression or the course of therapy ; therefore , this result can not be used to infer the presence or absence of a mutation in another sample or sub-sample obtained from this tumor .","{Mutation,status,in,a,sample,may,change,during,tumor,progression,or,the,course,of,therapy,;,therefore,,,this,result,can,not,be,used,to,infer,the,presence,or,absence,of,a,mutation,in,another,sample,or,sub-sample,obtained,from,this,tumor,.}","{mutation,status,in,a,sample,may,change,during,tumor,progression,or,the,course,of,therapy,;,therefore,,,this,result,can,not,be,use,to,infer,the,presence,or,absence,of,a,mutation,in,another,sample,or,sub-sample,obtain,from,this,tumor,.}","{NN,NN,IN,DT,NN,MD,VB,IN,NN,NN,CC,DT,NN,IN,NN,:,RB,,,DT,NN,MD,RB,VB,VBN,TO,VB,DT,NN,CC,NN,IN,DT,NN,IN,DT,NN,CC,JJ,VBN,IN,DT,NN,.}","{2,7,0,5,2,7,0,0,10,7,0,13,10,0,13,0,24,0,20,24,24,24,24,7,26,24,28,26,0,28,0,33,28,0,36,33,0,33,38,0,42,39,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_112,"This test is validated for non-small cell lung carcinoma .","{This,test,is,validated,for,non-small,cell,lung,carcinoma,.}","{this,test,be,validate,for,non-small,cell,lung,carcinoma,.}","{DT,NN,VBZ,VBN,IN,JJ,NN,NN,NN,.}","{2,4,4,0,0,9,9,9,4,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_113,"The clinical signi?cance and utility of this test in other tumor types is unknown .","{The,clinical,signi?cance,and,utility,of,this,test,in,other,tumor,types,is,unknown,.}","{the,clinical,signi?cance,and,utility,of,this,test,in,other,tumor,type,be,unknown,.}","{DT,JJ,NN,CC,NN,IN,DT,NN,IN,JJ,NN,NNS,VBZ,JJ,.}","{3,3,14,0,14,0,8,3,0,12,12,8,14,0,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_114,"METHOD/LIMITATION : Tissue sections are reviewed by a pathologist and relevant tumor is selected for analysis .","{METHOD/LIMITATION,:,Tissue,sections,are,reviewed,by,a,pathologist,and,relevant,tumor,is,selected,for,analysis,.}","{METHOD/LIMITATION,:,tissue,section,be,review,by,a,pathologist,and,relevant,tumor,be,select,for,analysis,.}","{NNP,:,NN,NNS,VBP,VBN,IN,DT,NN,CC,JJ,NN,VBZ,VBN,IN,NN,.}","{0,0,4,6,6,1,0,9,6,0,12,14,14,6,0,14,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_115,"DNA is isolated from the samples , quanti?ed and amplified by polymerase chain reaction ( PCR ) using primers to exons 18-21 of the EGF R gene .","{DNA,is,isolated,from,the,samples,,,quanti?ed,and,amplified,by,polymerase,chain,reaction,(,PCR,),using,primers,to,exons,18-21,of,the,EGF,R,gene,.}","{dna,be,isolate,from,the,sample,,,quanti?ed,and,amplify,by,polymerase,chain,reaction,(,pcr,),use,primer,to,exon,18-21,of,the,egf,r,gene,.}","{NN,VBZ,VBN,IN,DT,NNS,,,VBN,CC,VBN,IN,NN,NN,NN,CD,NN,NN,VBG,NNS,TO,NNS,CD,IN,DT,NN,NN,NN,.}","{10,3,0,0,6,3,0,3,0,3,0,17,17,17,17,17,10,17,18,0,18,21,0,27,27,27,21,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_116,"PCR products are analyzed by bi-directional direct DNA sequencing using capillary gel electrophoresis and ?uorescence detection .","{PCR,products,are,analyzed,by,bi-directional,direct,DNA,sequencing,using,capillary,gel,electrophoresis,and,?uorescence,detection,.}","{pcr,product,be,analyze,by,bi-directional,direct,dna,sequencing,use,capillary,gel,electrophoresis,and,?uorescence,detection,.}","{NN,NNS,VBP,VBN,IN,JJ,JJ,NN,NN,VBG,JJ,NN,NN,CC,NN,NN,.}","{2,4,4,0,0,9,9,9,4,9,13,13,10,0,16,13,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_117,"False positive or negative results may occur for reasons that include genetic variants or somatic heterogeneity of the tissue sample .","{False,positive,or,negative,results,may,occur,for,reasons,that,include,genetic,variants,or,somatic,heterogeneity,of,the,tissue,sample,.}","{false,positive,or,negative,result,may,occur,for,reason,that,include,genetic,variant,or,somatic,heterogeneity,of,the,tissue,sample,.}","{JJ,JJ,CC,JJ,NNS,MD,VB,IN,NNS,WDT,VBP,JJ,NNS,CC,JJ,NN,IN,DT,NN,NN,.}","{5,5,0,2,7,7,0,0,7,11,9,13,11,0,16,13,0,20,20,16,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_118,"REFERENCES : 1 .","{REFERENCES,:,1,.}","{reference,:,1,.}","{NNS,:,CD,.}","{0,0,1,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_119,"Azzoli CG , et al , J. Clin Oncol .","{Azzoli,CG,,,et,al,,,J.,Clin,Oncol,.}","{Azzoli,CG,,,et,al,,,J.,Clin,Oncol,.}","{NNP,NNP,,,FW,FW,,,NNP,NNP,NNP,.}","{2,0,0,5,2,0,9,9,5,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_120,"2009 ; 27:6251 -6266 .","{2009,;,27:6251,-6266,.}","{2009,;,27:6251,-6266,.}","{CD,:,CD,CD,.}","{0,0,4,1,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_121,"2 .","{2,.}","{2,.}","{LS,.}","{0,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_122,"Jackman DM , e t al. .","{Jackman,DM,,,e,t,al.,.}","{Jackman,dm,,,e,t,al.,.}","{NNP,NN,,,LS,NN,FW,.}","{2,0,0,5,2,5,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_123,"Clin Carcinoma Res .","{Clin,Carcinoma,Res,.}","{Clin,Carcinoma,Res,.}","{NNP,NNP,NNP,.}","{3,3,0,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_124,"2009 ; l5 :5267 -5273 .","{2009,;,l5,:5267,-5273,.}","{2009,;,l5,:5267,-5273,.}","{CD,:,CD,CD,CD,.}","{0,0,1,5,3,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_125,"3 .","{3,.}","{3,.}","{LS,.}","{0,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_126,"Mok TS , et al. .","{Mok,TS,,,et,al.,.}","{mok,t,,,et,al.,.}","{NN,NN,,,FW,FW,.}","{2,0,0,5,2,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_127,"N Engl J Med .","{N,Engl,J,Med,.}","{n,Engl,J,Med,.}","{NN,NNP,NNP,NNP,.}","{0,4,4,1,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_128,"2009 ; 361:947 -957 .","{2009,;,361:947,-957,.}","{2009,;,361:947,-957,.}","{CD,:,CD,CD,.}","{0,0,4,1,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_129,"4 .","{4,.}","{4,.}","{LS,.}","{0,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_130,"Sharma SV , et al. .","{Sharma,SV,,,et,al.,.}","{sharma,sv,,,et,al.,.}","{FW,FW,,,FW,FW,.}","{2,0,0,5,2,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_131,"Nat Rev Carcinoma .","{Nat,Rev,Carcinoma,.}","{Nat,rev,carcinoma,.}","{NNP,NN,NN,.}","{0,3,1,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_132,"2007 ; 7 : 169-181 .","{2007,;,7,:,169-181,.}","{2007,;,7,:,169-181,.}","{CD,:,CD,:,CD,.}","{0,0,5,0,1,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_133,"DISCLAIMER :","{DISCLAIMER,:}","{DISCLAIMER,:}","{NNP,:}","{0,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_134,"The test was developed and its performance characteristics determined by _ he laboratory is regulated under the Clinical Laboratory Improvement Amendments of 1988 ( CLIA ) as quali?ed to perform high complexity clinical testing .","{The,test,was,developed,and,its,performance,characteristics,determined,by,_,he,laboratory,is,regulated,under,the,Clinical,Laboratory,Improvement,Amendments,of,1988,(,CLIA,),as,quali?ed,to,perform,high,complexity,clinical,testing,.}","{the,test,be,develop,and,its,performance,characteristic,determine,by,_,he,laboratory,be,regulate,under,the,clinical,laboratory,improvement,amendment,of,1988,(,clium,),as,quali?ed,to,perform,high,complexity,clinical,testing,.}","{DT,NN,VBD,VBN,CC,PRP$,NN,NNS,VBN,IN,NN,PRP,NN,VBZ,VBN,IN,DT,JJ,NN,NN,NNS,IN,CD,CD,NN,RB,IN,JJ,TO,VB,JJ,NN,JJ,NN,.}","{2,4,4,0,0,8,8,9,4,0,9,9,15,15,12,0,21,21,21,21,15,0,25,25,21,28,28,25,30,15,34,34,34,30,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_135,"This particular test is not considered a stand alone test and should be used only in the context of other diagnostic tests or clinical work-up related to treatment decisions .","{This,particular,test,is,not,considered,a,stand,alone,test,and,should,be,used,only,in,the,context,of,other,diagnostic,tests,or,clinical,work-up,related,to,treatment,decisions,.}","{this,particular,test,be,not,consider,a,stand,alone,test,and,should,be,use,only,in,the,context,of,other,diagnostic,test,or,clinical,work-up,related,to,treatment,decision,.}","{DT,JJ,NN,VBZ,RB,VBN,DT,NN,RB,NN,CC,MD,VB,VBN,RB,IN,DT,NN,IN,JJ,JJ,NNS,CC,JJ,NN,JJ,TO,NN,NNS,.}","{3,3,14,6,6,0,10,10,10,6,0,14,14,6,14,0,18,14,0,22,22,18,0,25,14,25,0,29,26,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_136,"Electronically signed by : Date .","{Electronically,signed,by,:,Date,.}","{electronically,sign,by,:,date,.}","{RB,VBN,IN,:,NN,.}","{0,1,2,0,2,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_137,"Addendum","{Addendum}","{Addendum}","{NNP}","{0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_138,"# 2 performed by","{#,2,performed,by}","{#,2,perform,by}","{#,CD,VBN,IN}","{2,3,0,3}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_139,"The electronic signature attests that the named Attending Pathologist has evaluated the specimen referred to in the signed section of the report and formulated the diagnosis therein .","{The,electronic,signature,attests,that,the,named,Attending,Pathologist,has,evaluated,the,specimen,referred,to,in,the,signed,section,of,the,report,and,formulated,the,diagnosis,therein,.}","{the,electronic,signature,attest,that,the,name,attend,pathologist,have,evaluate,the,specimen,refer,to,in,the,sign,section,of,the,report,and,formulate,the,diagnosis,therein,.}","{DT,JJ,NN,VBZ,IN,DT,VBN,VBG,NN,VBZ,VBN,DT,NN,VBD,TO,IN,DT,VBN,NN,IN,DT,NN,CC,VBD,DT,NN,RB,.}","{3,3,4,0,11,11,6,7,8,11,4,13,24,11,14,0,19,19,14,0,22,19,0,14,26,24,24,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_140,"This report may include one or more immunohistochemical stain results that use analyte speci?c reagents .","{This,report,may,include,one,or,more,immunohistochemical,stain,results,that,use,analyte,speci?c,reagents,.}","{this,report,may,include,one,or,more,immunohistochemical,stain,result,that,use,analyte,speci?c,reagent,.}","{DT,NN,MD,VB,CD,CC,JJR,JJ,VB,NNS,WDT,VBP,NN,NN,NNS,.}","{2,4,4,0,8,0,8,9,4,9,12,10,15,15,12,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_141,"The tests were developed and their performance characteristics determined by","{The,tests,were,developed,and,their,performance,characteristics,determined,by}","{the,test,be,develop,and,they,performance,characteristic,determine,by}","{DT,NNS,VBD,VBN,CC,PRP$,NN,NNS,VBN,IN}","{2,9,4,0,0,8,8,9,4,9}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_142,"They have not been cleared or approved by the US Food and Drug Administration .","{They,have,not,been,cleared,or,approved,by,the,US,Food,and,Drug,Administration,.}","{they,have,not,be,clear,or,approve,by,the,US,Food,and,Drug,Administration,.}","{PRP,VBP,RB,VBN,VBN,CC,VBN,IN,DT,NNP,NNP,CC,NNP,NNP,.}","{7,5,5,5,0,0,5,0,11,11,5,0,14,5,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_143,"The FDA has determined that such clearance or approval is not necessary .","{The,FDA,has,determined,that,such,clearance,or,approval,is,not,necessary,.}","{the,FDA,have,determine,that,such,clearance,or,approval,be,not,necessary,.}","{DT,NNP,VBZ,VBN,IN,JJ,NN,CC,NN,VBZ,RB,JJ,.}","{2,4,4,0,12,7,12,0,12,12,12,4,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_144,"Zrilrwia .","{Zrilrwia,.}","{Zrilrwia,.}","{NNP,.}","{0,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_145,"_ , _ :2 ; agnosis Discrepancy vnm.-iry Tumor Site Dis ( repar | cf .","{_,,,_,:2,;,agnosis,Discrepancy,vnm.-iry,Tumor,Site,Dis,(,repar,|,cf,.}","{_,,,_,:2,;,agnosis,discrepancy,vnm.-iry,tumor,site,Dis,(,repar,|,cf,.}","{NN,,,CD,CD,:,NN,NN,JJ,NN,NN,NNP,CD,JJ,NN,NN,.}","{0,0,4,1,0,7,1,11,11,11,7,15,15,15,7,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_146,"? .","{?,.}","{?,.}","{NN,.}","{0,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_147,".","{.}","{.}","{.}","{0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_148,"~ .","{~,.}","{~,.}","{NN,.}","{0,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_149,"? .","{?,.}","{?,.}","{NN,.}","{0,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_150,".","{.}","{.}","{.}","{0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_151,"? .","{?,.}","{?,.}","{NN,.}","{0,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_152,".","{.}","{.}","{.}","{0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_153,"? .","{?,.}","{?,.}","{NN,.}","{0,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_154,"HIPAA Di $ LI'E , ' .","{HIPAA,Di,$,LI'E,,,',.}","{HIPAA,Di,$,li'e,,,',.}","{NNP,NNP,$,CD,,,'',.}","{0,1,2,3,0,0,0}","{}"
TCGA-97-A4M0, TCGA-97-A4M0SENT_155,"iil1CV ? Print Malignancy Hisfcr","{iil1CV,?,Print,Malignancy,Hisfcr}","{iil1cv,?,print,malignancy,hisfcr}","{NN,CD,NN,NN,NN}","{0,3,1,5,1}","{}"
